Iliana Micali
Internal Medicine · Federal Way, WANPI 1134128788
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 378 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,908, 2.3 times the $1,269 reported in 2019. Among internal medicine clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 378 payments — averaging $33.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Amgen$884
- AbbVie$700
- plus $6K from 35 others
What the payments were for
- Food & beverage$12,27498%
- Education$2282%
- Other$500%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,553 in reported general payments places this provider in the 95th percentile of 2,038 internal medicine providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 205 | $178,452 |
| OzempicSemaglutide | 93 | $94,718 |
| RybelsusSemaglutide | 42 | $49,068 |
| JanuviaSitagliptin Phosphate | 52 | $47,710 |
| TrulicityDulaglutide | 34 | $39,063 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $38,831 |
| FarxigaDapagliflozin Propanediol | 26 | $29,343 |
| Repatha SureclickEvolocumab | 19 | $27,403 |
| EliquisApixaban | 24 | $25,312 |
| TradjentaLinagliptin | 18 | $10,987 |
| Varenicline Tartrate | 12 | $3,730 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $3,458 |
| Atorvastatin Calcium | 419 | $3,451 |
| Omeprazole | 193 | $3,351 |
| Wixela InhubFluticasone Propion/Salmeterol | 20 | $3,115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $683 | $189,440223 claims |
| Novo NordiskOzempic, Rybelsus | $1,012 | $143,786135 claims |
| MerckJanuvia | $34 | $47,71052 claims |
| Lilly USA, LLCTrulicity, Olanzapine | $1,213 | $39,70283 claims |
| GSKTrelegy Ellipta | $1,316 | $38,83155 claims |
| AstraZenecaFarxiga | $1,837 | $29,34326 claims |
| PfizerEliquis | $88 | $25,31224 claims |
| AbbVieSynthroid | $700 | $2,11218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,038 internal medicine providers in Washington.
Other internal medicine in Federal Way
- Peter ShalitSeattle$1M
- Lawrence LoebBellevue$784K
- Shawna PurcellOlympia$294K
- Scott RamseySeattle$230K
- Michael CairnsSeattle$144K
- Peiqing QianSeattle$117K
- Alan KellySpokane Valley$96K
- Emily EgdaminWenatchee$81K
- Royce MorrisonTacoma$72K
- Safoora ZakaPort Orchard$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.